La Jolla Pharmaceutical Co. (NASDAQ:LJPC) rose 4.3% during trading on Wednesday . The company traded as high as $17.21 and last traded at $17.10, with a volume of 59,769 shares changing hands. The stock had previously closed at $16.39.

LJPC has been the subject of a number of recent research reports. Lake Street Capital initiated coverage on La Jolla Pharmaceutical in a research report on Tuesday, May 24th. They set a “buy” rating and a $25.00 price objective for the company. SunTrust Banks Inc. initiated coverage on La Jolla Pharmaceutical in a research report on Wednesday, June 22nd. They set a “buy” rating and a $30.00 price objective for the company. Zacks Investment Research upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. Finally, Jefferies Group reiterated a “buy” rating on shares of La Jolla Pharmaceutical in a research report on Wednesday, June 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $39.50.

The stock’s market cap is $307.76 million. The stock’s 50 day moving average is $16.70 and its 200 day moving average is $17.49.

La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its quarterly earnings results on Friday, May 6th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.22. On average, analysts anticipate that La Jolla Pharmaceutical Co. will post ($3.99) earnings per share for the current year.

An institutional investor recently raised its position in La Jolla Pharmaceutical stock. P.A.W. Capital Corp increased its position in shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC) by 5.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,400 shares of the biopharmaceutical company’s stock after buying an additional 2,400 shares during the period. La Jolla Pharmaceutical accounts for approximately 1.5% of P.A.W. Capital Corp’s investment portfolio, making the stock its 28th largest position. P.A.W. Capital Corp owned 0.28% of La Jolla Pharmaceutical worth $1,361,000 as of its most recent filing with the SEC.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.